Extending the spectrum of precompetitive collaboration in oncology research: workshop summary
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
National Academies Press
c2010
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Includes bibliographical references (p. 80-83) Introduction -- Current driving forces for collaboration -- Benefits of collaborating -- Challenges to collaborating -- What to share -- Types of precompetitive collaborations -- Lessons learned -- Next steps -- Summary "Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings."--Publisher's description |
| Beschreibung: | 1 Online-Ressource (xiv, 97 p.) |
| ISBN: | 0309156556 1282787543 9780309156554 9781282787544 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043144368 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2010 |||| o||u| ||||||eng d | ||
| 020 | |a 0309156556 |c electronic bk. |9 0-309-15655-6 | ||
| 020 | |a 1282787543 |9 1-282-78754-3 | ||
| 020 | |a 9780309156554 |c electronic bk. |9 978-0-309-15655-4 | ||
| 020 | |a 9781282787544 |9 978-1-282-78754-4 | ||
| 035 | |a (OCoLC)676821806 | ||
| 035 | |a (DE-599)BVBBV043144368 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 616.99400157488 |2 22 | |
| 245 | 1 | 0 | |a Extending the spectrum of precompetitive collaboration in oncology research |b workshop summary |c Margie Patlak, Sharyl J. Nass, and Erin Balogh, rapporteurs ; National Cancer Policy Forum ; Board on Health Care Services ; Institute of Medicine of the National Academies |
| 264 | 1 | |a Washington, D.C. |b National Academies Press |c c2010 | |
| 300 | |a 1 Online-Ressource (xiv, 97 p.) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references (p. 80-83) | ||
| 500 | |a Introduction -- Current driving forces for collaboration -- Benefits of collaborating -- Challenges to collaborating -- What to share -- Types of precompetitive collaborations -- Lessons learned -- Next steps -- Summary | ||
| 500 | |a "Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development | ||
| 500 | |a While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings."--Publisher's description | ||
| 650 | 4 | |a Biomedical Research / economics / United States / Congresses | |
| 650 | 4 | |a Neoplasms / United States / Congresses | |
| 650 | 4 | |a Cooperative Behavior / United States / Congresses | |
| 650 | 4 | |a Industry / United States / Congresses | |
| 650 | 4 | |a Public-Private Sector Partnerships / United States / Congresses | |
| 650 | 4 | |a Schools / United States / Congresses | |
| 650 | 7 | |a MEDICAL / Oncology |2 bisacsh | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / Cancer |2 bisacsh | |
| 650 | 7 | |a Academic-industrial collaboration |2 fast | |
| 650 | 7 | |a Cancer / Research |2 fast | |
| 650 | 7 | |a Oncology / Research |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Oncology |x Research |z United States |v Congresses | |
| 650 | 4 | |a Cancer |x Research |z United States |v Congresses | |
| 650 | 4 | |a Academic-industrial collaboration |z United States |v Congresses | |
| 651 | 4 | |a USA | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 700 | 1 | |a Patlak, Margie |e Sonstige |4 oth | |
| 700 | 1 | |a Nass, Sharyl J. |e Sonstige |4 oth | |
| 700 | 1 | |a Balogh, Erin |e Sonstige |4 oth | |
| 710 | 2 | |a National Cancer Policy Forum (U.S.) |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Board on Health Care Services |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 0-309-15654-8 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-309-15654-7 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028568559 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175597040041984 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043144368 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)676821806 (DE-599)BVBBV043144368 |
| dewey-full | 616.99400157488 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99400157488 |
| dewey-search | 616.99400157488 |
| dewey-sort | 3616.99400157488 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05391nmm a2200673zc 4500</leader><controlfield tag="001">BV043144368</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2010 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309156556</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-309-15655-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1282787543</subfield><subfield code="9">1-282-78754-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309156554</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-309-15655-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781282787544</subfield><subfield code="9">978-1-282-78754-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)676821806</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043144368</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99400157488</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Extending the spectrum of precompetitive collaboration in oncology research</subfield><subfield code="b">workshop summary</subfield><subfield code="c">Margie Patlak, Sharyl J. Nass, and Erin Balogh, rapporteurs ; National Cancer Policy Forum ; Board on Health Care Services ; Institute of Medicine of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">c2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xiv, 97 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (p. 80-83)</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Introduction -- Current driving forces for collaboration -- Benefits of collaborating -- Challenges to collaborating -- What to share -- Types of precompetitive collaborations -- Lessons learned -- Next steps -- Summary</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings."--Publisher's description</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomedical Research / economics / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cooperative Behavior / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industry / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public-Private Sector Partnerships / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Schools / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Oncology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / Cancer</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Academic-industrial collaboration</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer / Research</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncology / Research</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield><subfield code="x">Research</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Research</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Academic-industrial collaboration</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patlak, Margie</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nass, Sharyl J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balogh, Erin</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Cancer Policy Forum (U.S.)</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Board on Health Care Services</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">0-309-15654-8</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-309-15654-7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028568559</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043144368 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:18:49Z |
| institution | BVB |
| isbn | 0309156556 1282787543 9780309156554 9781282787544 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028568559 |
| oclc_num | 676821806 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (xiv, 97 p.) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Extending the spectrum of precompetitive collaboration in oncology research workshop summary Margie Patlak, Sharyl J. Nass, and Erin Balogh, rapporteurs ; National Cancer Policy Forum ; Board on Health Care Services ; Institute of Medicine of the National Academies Washington, D.C. National Academies Press c2010 1 Online-Ressource (xiv, 97 p.) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references (p. 80-83) Introduction -- Current driving forces for collaboration -- Benefits of collaborating -- Challenges to collaborating -- What to share -- Types of precompetitive collaborations -- Lessons learned -- Next steps -- Summary "Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings."--Publisher's description Biomedical Research / economics / United States / Congresses Neoplasms / United States / Congresses Cooperative Behavior / United States / Congresses Industry / United States / Congresses Public-Private Sector Partnerships / United States / Congresses Schools / United States / Congresses MEDICAL / Oncology bisacsh HEALTH & FITNESS / Diseases / Cancer bisacsh Academic-industrial collaboration fast Cancer / Research fast Oncology / Research fast Medizin Oncology Research United States Congresses Cancer Research United States Congresses Academic-industrial collaboration United States Congresses USA (DE-588)1071861417 Konferenzschrift gnd-content Patlak, Margie Sonstige oth Nass, Sharyl J. Sonstige oth Balogh, Erin Sonstige oth National Cancer Policy Forum (U.S.) Sonstige oth Institute of Medicine (U.S.) Board on Health Care Services Sonstige oth Erscheint auch als Druckausgabe 0-309-15654-8 Erscheint auch als Druckausgabe 978-0-309-15654-7 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808 Aggregator Volltext |
| spellingShingle | Extending the spectrum of precompetitive collaboration in oncology research workshop summary Biomedical Research / economics / United States / Congresses Neoplasms / United States / Congresses Cooperative Behavior / United States / Congresses Industry / United States / Congresses Public-Private Sector Partnerships / United States / Congresses Schools / United States / Congresses MEDICAL / Oncology bisacsh HEALTH & FITNESS / Diseases / Cancer bisacsh Academic-industrial collaboration fast Cancer / Research fast Oncology / Research fast Medizin Oncology Research United States Congresses Cancer Research United States Congresses Academic-industrial collaboration United States Congresses |
| subject_GND | (DE-588)1071861417 |
| title | Extending the spectrum of precompetitive collaboration in oncology research workshop summary |
| title_auth | Extending the spectrum of precompetitive collaboration in oncology research workshop summary |
| title_exact_search | Extending the spectrum of precompetitive collaboration in oncology research workshop summary |
| title_full | Extending the spectrum of precompetitive collaboration in oncology research workshop summary Margie Patlak, Sharyl J. Nass, and Erin Balogh, rapporteurs ; National Cancer Policy Forum ; Board on Health Care Services ; Institute of Medicine of the National Academies |
| title_fullStr | Extending the spectrum of precompetitive collaboration in oncology research workshop summary Margie Patlak, Sharyl J. Nass, and Erin Balogh, rapporteurs ; National Cancer Policy Forum ; Board on Health Care Services ; Institute of Medicine of the National Academies |
| title_full_unstemmed | Extending the spectrum of precompetitive collaboration in oncology research workshop summary Margie Patlak, Sharyl J. Nass, and Erin Balogh, rapporteurs ; National Cancer Policy Forum ; Board on Health Care Services ; Institute of Medicine of the National Academies |
| title_short | Extending the spectrum of precompetitive collaboration in oncology research |
| title_sort | extending the spectrum of precompetitive collaboration in oncology research workshop summary |
| title_sub | workshop summary |
| topic | Biomedical Research / economics / United States / Congresses Neoplasms / United States / Congresses Cooperative Behavior / United States / Congresses Industry / United States / Congresses Public-Private Sector Partnerships / United States / Congresses Schools / United States / Congresses MEDICAL / Oncology bisacsh HEALTH & FITNESS / Diseases / Cancer bisacsh Academic-industrial collaboration fast Cancer / Research fast Oncology / Research fast Medizin Oncology Research United States Congresses Cancer Research United States Congresses Academic-industrial collaboration United States Congresses |
| topic_facet | Biomedical Research / economics / United States / Congresses Neoplasms / United States / Congresses Cooperative Behavior / United States / Congresses Industry / United States / Congresses Public-Private Sector Partnerships / United States / Congresses Schools / United States / Congresses MEDICAL / Oncology HEALTH & FITNESS / Diseases / Cancer Academic-industrial collaboration Cancer / Research Oncology / Research Medizin Oncology Research United States Congresses Cancer Research United States Congresses Academic-industrial collaboration United States Congresses USA Konferenzschrift |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=338808 |
| work_keys_str_mv | AT patlakmargie extendingthespectrumofprecompetitivecollaborationinoncologyresearchworkshopsummary AT nasssharylj extendingthespectrumofprecompetitivecollaborationinoncologyresearchworkshopsummary AT balogherin extendingthespectrumofprecompetitivecollaborationinoncologyresearchworkshopsummary AT nationalcancerpolicyforumus extendingthespectrumofprecompetitivecollaborationinoncologyresearchworkshopsummary AT instituteofmedicineusboardonhealthcareservices extendingthespectrumofprecompetitivecollaborationinoncologyresearchworkshopsummary |